NVNO — enVVeno Medical Corp
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1661053 ·
Last close
$10.35
Market Cap
$7.07M
52W High
$12.49
52W Low
$9.69
ADV30
19,282
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,796,000 | -3,600,000 | 22,660,000 | 2,841,000 | 1,990,000 |
| Mar 2026 | 0 | — | -4,062,000 | -3,849,000 | 26,097,000 | 2,597,000 | 2,350,000 |
| Dec 2025 | 0 | — | -4,013,000 | -3,736,000 | 29,562,000 | 3,065,000 | 2,432,000 |
| Sep 2025 | 0 | — | -4,883,000 | -4,539,000 | 32,352,000 | 1,544,000 | 2,905,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,622,000
Investing CF
$14,270,000
Financing CF
$1,023,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-30.83
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-178,776,000
Inventory
—
Receivables
—
ST Investments
$18,645,000
EBIT TTM
$-16,754,000
Pretax Income TTM
$-15,724,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,899,000 | -19,472,000 | 29,562,000 | 2,432,000 | — | -15,568,000 |
| Dec 2024 | 0 | -23,826,000 | -21,819,000 | 44,954,000 | 2,795,000 | — | -16,838,000 |
| Dec 2023 | 0 | -25,238,000 | -23,516,000 | 48,635,000 | 2,435,000 | — | -18,858,000 |
| Dec 2022 | 0 | -24,932,000 | -24,669,000 | 41,661,000 | 2,932,000 | — | -15,619,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.22
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NXL | Nexalin Technology, Inc. | $6.95M | $0.32 | — |
| NDRA | ENDRA Life Sciences Inc. | $6.84M | $4.56 | — |
| INBS | INTELLIGENT BIO SOLUTIONS INC. | $7.55M | $2.50 | — |
| CODX | Co-Diagnostics, Inc. | $7.63M | $1.22 | — |
| ICCM | IceCure Medical Ltd. | $7.78M | $2.27 | — |
News headlines (Yahoo Finance, 1h cache)
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
2026-07-31 12:30 · Yahoo
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
2026-07-15 12:30 · Yahoo
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
2026-07-07 12:29 · Yahoo
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
2026-06-22 13:00 · Yahoo
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
2026-06-02 13:01 · Yahoo
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
2026-05-07 12:05 · Yahoo
One enVVeno Medical Insider Raised Their Stake In The Previous Year
2026-05-06 18:58 · Yahoo
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
2026-04-29 12:05 · Yahoo
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatm
2026-08-04 12:46 · Yahoo
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
2026-05-12 13:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.